Cellectar Biosciences Inc... (CLRB)
Cellectar Biosciences Statistics
Share Statistics
Cellectar Biosciences has 46.08M shares outstanding. The number of shares has increased by 28.54% in one year.
| Shares Outstanding | 46.08M |
| Shares Change (YoY) | 28.54% |
| Shares Change (QoQ) | 11.66% |
| Owned by Institutions (%) | 13.92% |
| Shares Floating | 45.31M |
| Failed to Deliver (FTD) Shares | 33.45K |
| FTD / Avg. Volume | 2.89% |
Short Selling Information
The latest short interest is 2.22M, so 4.83% of the outstanding shares have been sold short.
| Short Interest | 2.22M |
| Short % of Shares Out | 4.83% |
| Short % of Float | 5.32% |
| Short Ratio (days to cover) | 2.2 |
Valuation Ratios
The PE ratio is -0.25 and the forward PE ratio is -0.43. Cellectar Biosciences's PEG ratio is 0.
| PE Ratio | -0.25 |
| Forward PE | -0.43 |
| PS Ratio | 0 |
| Forward PS | 0.3 |
| PB Ratio | 0.77 |
| P/FCF Ratio | -0.23 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Cellectar Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.58, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.58 |
| Quick Ratio | 2.58 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-4.05M |
| Employee Count | 11 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 66K |
| Effective Tax Rate | -0.15% |
Stock Price Statistics
The stock price has increased by -89.87% in the last 52 weeks. The beta is 0.67, so Cellectar Biosciences's price volatility has been higher than the market average.
| Beta | 0.67 |
| 52-Week Price Change | -89.87% |
| 50-Day Moving Average | 0.31 |
| 200-Day Moving Average | 1.26 |
| Relative Strength Index (RSI) | 53.22 |
| Average Volume (20 Days) | 1.16M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -51.78M |
| Net Income | -44.58M |
| EBITDA | -51.78M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.22 |
Balance Sheet
The company has 23.29M in cash and 494K in debt, giving a net cash position of 22.79M.
| Cash & Cash Equivalents | 23.29M |
| Total Debt | 494K |
| Net Cash | 22.79M |
| Retained Earnings | -247.34M |
| Total Assets | 25.47M |
| Working Capital | 14.86M |
Cash Flow
In the last 12 months, operating cash flow was -47.58M and capital expenditures -104.19K, giving a free cash flow of -47.69M.
| Operating Cash Flow | -47.58M |
| Capital Expenditures | -104.19K |
| Free Cash Flow | -47.69M |
| FCF Per Share | -1.3 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CLRB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CLRB is $28, which is 8932.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $28 |
| Price Target Difference | 8932.3% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jul 22, 2022. It was a backward split with a ratio of 1:10.
| Last Split Date | Jul 22, 2022 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -18.86 |
| Piotroski F-Score | 1 |